Piper Sandler analyst Kelsey Goodwin lowered the firm’s price target on Janux Therapeutics (JANX) to $30 from $42 and keeps an Overweight rating on the shares. Following a flurry of updates from companies across its coverage, the firm updating its 2026 Catalyst Tracker, as well as several models and price targets.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Janux Therapeutics price target lowered to $35 from $49 at BofA
- 3 ‘Strong Buy’ Stocks to Buy Today,12/29/2025, According to Top Analysts
- Maintaining Buy on Janux: Trial Progress and Undervalued Pipeline Create Compelling Risk–Reward
- These Are the Most and Least Likely Biotech Takeover Targets for 2026
- Janux Therapeutics price target lowered to $29 from $48 at Barclays